Jeffrey Smoot has been an information scientist at CAS for 30 years. Prior to joining CAS, Jeffrey held a research position with Northwestern University and was a Hematology-Oncology Fellow at The Ohio State University. He obtained a B.A. in chemistry and a B.S. in biology from the University of California, Irvine and a PhD. in Biochemistry from The Ohio State University.
Latest Content from Jeffrey Smoot
November 30, 2021
Omicron variant accelerates need for more diverse COVID-19 vaccine strategy
Current vaccines against SARS-CoV-2 that target the spike protein are an important step toward developing antiviral therapeutics and next-generation vaccines. These vaccines have reduced hospitalizations and deaths. However, as the virus continues to mutate and evolve, solely targeting the spike protein may not be enough for protective immunity.